

**CENTER FOR DRUG EVALUATION AND
RESEARCH**

APPLICATION NUMBER:

212477Orig1s000

OFFICER/EMPLOYEE LIST

MEMORANDUM

DEPARTMENT OF HEALTH AND HUMAN SERVICES
PUBLIC HEALTH SERVICE
FOOD AND DRUG ADMINISTRATION
CENTER FOR DRUG EVALUATION AND RESEARCH

DATE: August 26, 2019

TO: Administrative file for NDA 212477

FROM: Philip Villasurda, PharmD, Regulatory Health Project Manager
Division of Antiviral Products, Office of Antimicrobial Products

SUBJECT: Officer/Employee List for NDA 212477

APPLICATION/DRUG: NDA 212477, HARVONTI®, ledipasvir/sofosbuvir, oral pellets

The following officers or employees of FDA participated in the decision to approve this application and consented to be identified on this list:

Birnkrant, Debra B
Chikhale, Elsbeth G
Choi, Su-Young
Davis, Nathan
Dorantes, Angelica
El-Kamary, Samer
Englund, Erika
Ghantous, Hanan
Griffiths, LaShawn
Harris, Sarah
Hassan, Hazem
Johnson, Anitra
Kolejian, Sevan
Lewis, David B
Li, Ruojing
Li, Zheng
Lunn, George
Min, Stacey
Mishra, Lalji
Murray, Jeffrey S
O'Rear, Julian
Ou, Mei
Soldatova, Lyudmila
Strayhorn, Suzanne

Struble, Kimberly
Swank, Kimberley
Walker, Morgan
Wilson, Valerie